

Can't fill your Estradiol/Norethindrone/Relugolix (Myfembree) prescription? Learn about alternative medications for uterine fibroids and endometriosis in 2026.
If you've been prescribed Estradiol/Norethindrone/Relugolix (brand name Myfembree) but can't fill it — whether because of availability issues, insurance denials, or cost — it's important to know that other treatment options exist for uterine fibroids and endometriosis.
This article covers what Estradiol/Norethindrone/Relugolix is, how it works, and several alternative medications your doctor may consider. Always talk to your prescriber before switching medications — this guide is for informational purposes only.
Myfembree is a once-daily oral tablet that combines three active ingredients in a single pill:
It's FDA-approved for:
For a detailed overview, see our guide on what Estradiol/Norethindrone/Relugolix is and how to take it.
The key ingredient, Relugolix, works by blocking GnRH receptors in the pituitary gland. This reduces the production of LH (luteinizing hormone) and FSH (follicle-stimulating hormone), which in turn lowers estrogen levels. Since uterine fibroids and endometriosis tissue are estrogen-dependent, reducing estrogen helps shrink fibroids and decrease endometriosis-related pain and bleeding.
The Estradiol and Norethindrone Acetate provide "add-back" therapy — just enough hormones to prevent severe bone loss and reduce uncomfortable symptoms like hot flashes, without undoing the therapeutic benefit. Learn more in our article on how Estradiol/Norethindrone/Relugolix works.
If you can't access Myfembree, the following medications treat similar conditions. Each has its own benefits, limitations, and side effect profile.
What it is: Oriahnn is the closest alternative to Myfembree. It's also a GnRH antagonist with built-in hormonal add-back therapy, FDA-approved for heavy menstrual bleeding from uterine fibroids.
How it's different:
Cost: Similar price range to Myfembree, around $1,000–$1,500/month without insurance. AbbVie offers a savings program for eligible patients.
What it is: Orilissa is a GnRH antagonist approved for moderate to severe endometriosis pain. Unlike Myfembree and Oriahnn, it does not include built-in add-back therapy.
How it's different:
Cost: Approximately $900–$1,200/month without insurance.
What it is: Lupron Depot is a GnRH agonist (not antagonist) given as an intramuscular injection — either monthly or every three months. It's used for both endometriosis and as preoperative treatment for uterine fibroids.
How it's different:
Cost: Approximately $1,000–$1,800 per injection without insurance, depending on the dose and frequency.
What it is: Levonorgestrel-releasing intrauterine devices (IUDs) like Mirena or Liletta are commonly used as first-line treatment for heavy menstrual bleeding, including bleeding caused by fibroids.
How it's different:
Cost: $0–$1,300 for insertion (often fully covered by insurance). No ongoing monthly medication cost.
The best alternative depends on your specific condition, medical history, and preferences. Consider these questions when talking to your doctor:
For help finding a provider, see our guide on how to find a doctor who prescribes Estradiol/Norethindrone/Relugolix.
Not being able to fill your Estradiol/Norethindrone/Relugolix (Myfembree) prescription is frustrating, but you do have options. Oriahnn, Orilissa, Lupron Depot, and hormonal IUDs can all be effective alternatives depending on your situation.
Before switching, we recommend trying to find Myfembree through specialty pharmacies or Medfinder first. If that's not possible, schedule a conversation with your prescriber to discuss which alternative makes the most sense for your health needs and budget.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.